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Abstract
Imaging colorectal cancer has become a major indication for positron emission tomography using fluorodeoxyglucose
(FDG–PET). In primary diagnosis and staging, the role for this technique is limited but FDG–PET has proved highly
accurate in the detection of recurrent tumour. The three main indications are (i) characterisation of a residual structural
lesion after definitive therapy, (ii) pre-operative staging prior to resection of apparently isolated metastasis, and (iii)
investigation of rising carcinoembryonic antigen (CEA) in a patient with normal structural imaging. The diagnostic
accuracy of FDG–PET translates to changes in management in a large number of patients, resulting in improved cost-
effectiveness. FDG–PET is fast becoming the standard of clinical care for patients with recurrent colorectal cancer.
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Introduction
Imaging colorectal cancer has become a major indication
for positron emission tomography (PET), following the
transition of this technology from the research arena into
clinical practice. Colorectal cancer is the second com-
monest tumour to be evaluated at the Wesley PET centre,
reflecting the high prevalence of this disease. PET is a
functional imaging technique that exploits the increased
glucose metabolism that occurs in colorectal cancer, and
many tumours, by depicting the distribution of the radio-
labelled glucose analogue, fluorine-18 fluorodeoxyglu-
cose (18F-FDG). The high impact of PET results from its
ability to detect tumour foci too small to be confidently
diagnosed by CT or other structural imaging methods.
This ability arises from the fact that lesion detection on
PET is determined by the magnitude of metabolic change
in the tumour, rather than tumour size.
Following a 6-hour fast to normalise serum glucose
levels, patients receive 185–370 MBq 18F-FDG intra-
venously, with imaging performed 45–60 min later.
Whole-body images are acquired using attenuation
correction to improve detection of deeply located
lesions. Iterative algorithms should be used for image
reconstruction to improve image quality and prevent
streak artefacts from areas of high activity, such as
excreted activity within the bladder. Combined PET/CT
systems allow for more rapid attenuation correction and
improved anatomical localisation of PET abnormalities
in some cases.
Role of FDG–PET in primary diagnosis
and staging
Primary colorectal cancers occasionally present as an
incidental finding on FDG–PET, and FDG uptake has
been reported in adenomatous polyps, a precursor to
colon cancer [1]. However, the presence of physiological
gut uptake of FDG combined with false-positive uptake
in inflammatory disease, along with low sensitivity to
lesions less than 1 cm, precludes a significant role for
FDG–PET in primary diagnosis or screening [2]. There
is evidence that FDG–PET is more accurate than CT
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Figure 1 Pelvic recurrence of colorectal cancer on CT (top left) and FDG–PET: transaxial (bottom left) and
sagittal (right) images.
in the primary staging of colorectal cancer. However,
FDG–PET in this setting appears to have little impact on
clinical management, due to the need for most patients to
undergo surgical resection of the primary tumour in order
to prevent subsequent bowel obstruction and due to the
importance that the results of pathological staging have in
determining prognosis and post-operative management.
Role of FDG–PET in recurrent
colorectal cancer
Recurrence rates after apparently curative resection of
colorectal cancer remain high, up to 40% in some
series [3]. Some patients will have a localised recurrence
that is amenable to surgical resection and potential cure.
The aim of imaging in such patients is to diagnose
the local recurrence and confirm the absence of other
disease sites that would preclude curative surgery. The
performance of current imaging strategies in this setting
has proved disappointing, with many patients thought
suitable for surgery being found to have unresectable
disease at operation [4]. FDG–PET is proving to have a
pivotal role in identifying those patients most likely to
benefit from surgical intervention.
Characterisation of residual structural lesion
after definitive therapy
Differentiation between pelvic recurrence and post-
operative fibrosis after excision of rectal tumour can be
problematic for CT and MRI (Fig. 1). A meta-analysis of
FDG–PET literature [4] determined a 95% sensitivity and
97% specificity for PET in this setting, whilst a direct
comparison of CT and FDG–PET reported sensitivity
values of 52 and 91% for CT and PET respectively,
along with enhanced specificity for PET (CT 80%,
PET 100%) [5]. Post-irradiation inflammatory change can
result in falsely positive uptake with PET [4], particularly
within 6–12 weeks of therapy.
FDG–PET can also be useful in characterising hepatic
or pulmonary lesions in patients who have previously
undergone resection of colon cancer. Although FDG–
PET often demonstrates hepatic metastases undetected by
CT, the overall accuracy for PET is only marginally better
than CT [5–8]. This finding is partly due to the background
hepatic uptake of FDG, which creates difficulty in
diagnosing hepatic metastases, particularly for lesions
less than 2 cm in diameter. For this reason, an FDG–
PET scan that is negative for hepatic metastases should
not be considered to exclude this diagnosis. There
has been little research to investigate the factors that
determine background hepatic uptake of FDG, although
our experience suggests background levels of FDG
activity are lower in patients with advanced disease and
poor survival.
Pre-operative staging prior to resection of
apparently isolated metastasis
Surgical resection of apparently isolated hepatic or
pulmonary metastasis from colorectal cancer results
in improved survival [3]. Accurate pre-operative staging
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of such patients is essential to avoid the morbidity
of surgery for patients with otherwise unsuspected
additional metastatic sites. There are now several
reports indicating superiority of PET over CT in this
clinical context [5–8], the greatest benefit arising from
detection of additional extra-hepatic tumour foci (Fig. 2).
Comparative sensitivity values for extra-hepatic disease
range from 58 to 74% for CT, vs. 90–100% for FDG–
PET, whilst specificity values are similar for the two
modalities. Exclusion of extra-hepatic metastases may
also be useful prior to aggressive local treatments for
hepatic metastases such as radiofrequency ablation or
intra-arterial microsphere-based radiotherapy.
Figure 2 Coronal FDG–PET image in a patient
with an hepatic metastasis from colorectal cancer
(straight arrow). A retro-peritoneal deposit unde-
tected by CT is also seen (curved arrow). (Note normal
myocardial and bladder activity.)
Investigation of rising carcinoembryonic
antigen (CEA) with normal structural imaging
The aim of imaging for patients with rising tumour
markers is to identify a localised tumour recurrence
that is potentially resectable with hope of a survival
benefit. CT typically provides the initial investigation
in such patients. However, when conventional imaging
is negative, the positive yield of FDG–PET ranges
between 38 and 77% [5,9,10]. Although FDG–PET may
reveal extensive inoperable disease in some cases,
a localised tumour deposit potentially amenable to
surgery is found in others. However, in a significant
proportion of these patients (25% in one series [10]), PET
is found to have underestimated the extent of disease at
surgery. Also, false-positive diagnoses, most commonly
inflammatory conditions, occasionally arise amongst
patients investigated for a rising CEA [9,10].
Therapeutic impact and
cost-effectiveness
Demonstration of therapeutic impact and cost-effecti-
veness is becoming increasingly important in the
evaluation of new diagnostic tests, and is often required
before funding can be obtained from governments or
health purchasers. A meta-analysis of PET literature in
recurrent colorectal cancer concludes that management is
altered in 29% (95% confidence interval 25–34%) [4]. In
most patients, FDG–PET results in upstaging of disease
with deferment of surgery [4,10]. Reported experience and
modelling approaches, such as decision-tree sensitivity
analysis, can demonstrate that these management changes

















Figure 3 Results from a decision-tree sensitivity
analysis for the use of FDG–PET to detect extra-
hepatic metastases prior to resection of an apparently
isolated hepatic metastasis. Using Australian medical
costs, the graph plots the incremental cost–accuracy
ratio (ICAR: i.e. the additional cost per additional
correctly managed patient) against the prevalence
of extra-hepatic disease for CT- and PET-based
management strategies. PET is more cost-effective
if the prevalence is above 0.18. (Typical reported
prevalence values are 0.3 or greater).
Summary
FDG–PET demonstrates high accuracy in detection of
recurrent colorectal cancer. This diagnostic performance
leads to changes in clinical management for a significant
proportion of patients, resulting in improved cost-
effectiveness. FDG–PET is fast becoming the standard
of clinical care for patients with known or suspected
recurrence of colorectal cancer.
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